MannKind Corporation to Hold 2021 First Quarter Financial Results Conference Call on May 12, 2021
May 05 2021 - 9:00AM
MannKind Corporation (Nasdaq:MNKD) will release
its 2021 first quarter financial results and its management will
host a conference call to discuss the financial results and
corporate updates at 5:00 PM (Eastern Time) on Wednesday, May 12,
2021.
Presenting from the Company will be its Chief
Executive Officer, Michael Castagna and Chief Financial Officer,
Steven B. Binder.
Those interested in listening to the conference
call live via the Internet may do so by visiting the Company's
website at http://www.mannkindcorp.com under Events &
Presentations. A replay will also be available on MannKind's
website for 14 days.
About MannKind Corporation
MannKind Corporation (NASDAQ: MNKD) focuses on
the development and commercialization of inhaled therapeutic
products for patients with endocrine and orphan lung diseases.
MannKind is currently commercializing Afrezza® (insulin human)
Inhalation Powder, the Company’s first FDA-approved product and the
only inhaled ultra rapid-acting mealtime insulin in the United
States, where it is available by prescription from pharmacies
nationwide. Afrezza is also available by prescription in Brazil
where it is commercialized by the Company’s partner Biomm SA.
MannKind is headquartered in Westlake Village, California, and has
a state-of-the art manufacturing facility in Danbury, Connecticut.
The Company also employs field sales and medical representatives
across the U.S. For further information, visit
www.mannkindcorp.com.
Company Contact: Phone: (818) 661-5000 Email:
ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jun 2024 to Jul 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jul 2023 to Jul 2024